Company Filing History:
Years Active: 2018-2021
Title: Cafer Yildiz: Innovator in Antibody Research
Introduction
Cafer Yildiz is a prominent inventor based in Arnhem, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents, his work focuses on innovative solutions for medical challenges.
Latest Patents
One of his latest patents is titled "Monoclonal antibodies against the active site of factor XI and uses thereof." This invention provides novel anti-factor XI (FXI) antibodies that specifically bind to the active center of FXI, inhibiting its functional activity. The patent also includes humanized versions of these antibodies, which are useful in preventing and treating conditions related to pathological thrombus formation or thrombo-embolism. Another significant patent is "Binding molecules that bind human complement factor C2 and uses thereof." This invention describes binding molecules with specific C2 activity inhibiting properties, which can be beneficial in treating various human diseases, including inflammatory and neuro-inflammatory diseases.
Career Highlights
Throughout his career, Cafer Yildiz has worked with notable companies such as Broteio Pharma B.V. and Prothix B.V. His expertise in antibody research has positioned him as a key figure in the biotechnology sector.
Collaborations
Cafer has collaborated with esteemed colleagues, including Cornelis Erik Hack and Louis Boon. These partnerships have further enhanced his research and development efforts in the field.
Conclusion
Cafer Yildiz is a distinguished inventor whose work in monoclonal antibodies has the potential to impact medical treatments significantly. His innovative patents and collaborations reflect his commitment to advancing biotechnology.